- Companies are doing at-home tests to find the right strain and dosage of marijuana to buy through their DNA.
- The tests are designed to help prevent bad trips and help with ailments like anxiety
- 43 states and Washington DC have varying degrees of legalization of cannabis
- Just over 31% of American adults suffer from anxiety and 90% of people with generalized anxiety disorder have symptoms of another mental health problem.
- Previous research finds ‘micro-dose’ of psychedelic drugs helped with various diseases
As marijuana continues to be legalized across America, a growing industry is emerging that will let customers trace the right strain and dosage through their DNA to help avoid bad trips and illnesses.
Companies like Endocana Health have created saliva kits that look for genetic traits similar to 23andMe, but for marijuana.
Endocana’s test looks at 57 genetic traits to see how a person reacts to marijuana.
Companies are doing at-home tests to find the right strain and dosage of marijuana to buy through their DNA.
Endocana’s $199 at-home test looks at 57 genetic traits to see how a person reacts to marijuana
The $199 kit looks for 57 different traits in 12 different categories, offering a ‘personalized wellness plan’ and ‘endo · aligned cannabinoid formulation suggestions. Company Website.
Once users register on the mydna.live website, they can spit their saliva onto a swab, then they are returned to a prepaid mailer that comes with the DNA kit.
The company then analyzes the swab and uploads a personalized report that provides a formula suggestion for the correct strain and dosage of marijuana.
Just over 31% of American adults suffer from anxiety and 90% of people with generalized anxiety disorder have symptoms of another mental health problem.
Endocana Health CEO Lane May said in an interview, ‘Your DNA is your blueprint’ bloomberg.
‘It gives you a GPS that can guide you to an experience that is more optimal and helps you avoid sharp corners.’
18 places in the black (17 states and the District of Columbia) have fully legalized marijuana. Overall, 43 states and the District of Columbia have varying degrees of legalization of cannabis.
Overall, 43 states and the District of Columbia have varying degrees of legalization of cannabis.
According to data from the National Institute of Mental Health, just over 31 percent of American adults suffer from anxiety and 90 percent of people with generalized anxiety disorder have symptoms of another mental health problem.
A study published in May found that 9 out of 10 patients who took MDMA, also known as ‘Molly’, saw a significant reduction in PTSD symptoms after three therapy sessions, compared to 6 out of 10. Placebo was used.
Psychedelic drugs being studied for their mental health benefits
In recent years, scientists have looked to psychedelic drugs as promising treatments for treatment-resistant mental illness.
Currently, such mind-altering drugs are largely illegal in the US.
But ongoing clinical trials suggest that the drugs once loved by hippies and club kids may have therapeutic benefits, too.
Scientists are investigating:
Club drugs and tranquilizers have been tested for the treatment of depression for many years.
In March 2019, the US Food and Drug Administration approved the first nasal spray version of the drug.
Ketamine works much more quickly than traditional antidepressants, and scientists believe it encourages new neural connections that may help overwrite unhealthy, depressive thought patterns.
The active ingredient in ‘magic mushroom’, psilocybin is a potent hallucinogen.
It also acts much more rapidly than conventional drugs and is being analyzed for use in patients with both depression and PTSD.
Psilocybin helps stimulate neuroplasticity and is believed to calm the ‘default mode network’ in the brain, and activate the ‘salience network’ involved in the drug.
In August, the FDA approved the largest clinical trial to date for psilocybin.
The club drug MDMA – sometimes referred to as ‘Molly’ – is currently in trials for the treatment of PTSD.
MDMA appears to calm activity in the amygdala and hippocampus, areas of the brain involved in emotional processing and fear responses, which are hyperactive in people with PTSD.
Patients participating in MDMA trials receive a single dose of the drug, and two stay in eight-hour sessions with therapists who guide their experience.
In May, researchers at UC Santa Cruz found that a non-hallucinating psychedelic similar to the psychoactive substance ibogaine significantly reduced stress levels in rats.
A separate study – also published in May – found that 9 out of 10 patients who took MDMA, also known as ‘molly’, saw a significant reduction in PTSD symptoms after three therapy sessions, while 6 out of 10 did. used placebo.
Companies are trying to figure out how people will react to cannabis and other psychedelic drugs such as psilocybin, MDMA, DMT and ketamine.
Enthion Biomedicals sells a mail-order $89 saliva test for people considering psychedelic drugs.
The company started out with the wish of CEO Timothy Coe to help his brother, who had become addicted to opioids and tried conventional treatments for mental illnesses without success. Ko’s brother died in 2019.
“The difficulty we faced as a family was a lot of uncertainty about exactly what he was suffering from and what medications he might be given,” Ko told Bloomberg.
These companies are trying to figure out how to give ‘micro-dose’ of psychedelic drugs or marijuana to reduce anxiety and cut the number of bad visits, or long-lasting psychosis, for those with , who seek alternative treatments for ailments such as depression, chronic pain. and other issues.
Berlin-based Atai Life Sciences is considering psychedelics drugs…